Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.

Sessink PJ, Connor TH, Jorgenson JA, Tyler TG.

J Oncol Pharm Pract. 2011 Mar;17(1):39-48. doi: 10.1177/1078155210361431. Epub 2010 Feb 15.

2.
3.
4.

Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.

Guillemette A, Langlois H, Voisine M, Merger D, Therrien R, Mercier G, Lebel D, Bussières JF.

J Oncol Pharm Pract. 2014 Dec;20(6):426-32. doi: 10.1177/1078155213517127. Epub 2014 Jan 6.

PMID:
24395542
5.

Environmental contamination by cyclophosphamide preparation: Comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo.

Schierl R, Masini C, Groeneveld S, Fischer E, Böhlandt A, Rosini V, Paolucci D.

J Oncol Pharm Pract. 2016 Feb;22(1):37-45. doi: 10.1177/1078155214551316. Epub 2014 Sep 16.

PMID:
25227229
6.

Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.

Clark BA, Sessink PJ.

J Oncol Pharm Pract. 2013 Jun;19(2):99-104. doi: 10.1177/1078155212468367. Epub 2013 Jan 4.

PMID:
23292973
7.

Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.

Siderov J, Kirsa S, McLauchlan R.

J Oncol Pharm Pract. 2010 Mar;16(1):19-25. doi: 10.1177/1078155209352543. Epub 2009 Dec 4.

PMID:
19965949
8.

Using a closed-system protective device to reduce personnel exposure to antineoplastic agents.

Wick C, Slawson MH, Jorgenson JA, Tyler LS.

Am J Health Syst Pharm. 2003 Nov 15;60(22):2314-20.

PMID:
14652980
9.

Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment.

Yoshida J, Tei G, Mochizuki C, Masu Y, Koda S, Kumagai S.

Ann Occup Hyg. 2009 Mar;53(2):153-60. doi: 10.1093/annhyg/men081.

PMID:
19261696
10.

Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators.

Crauste-Manciet S, Sessink PJ, Ferrari S, Jomier JY, Brossard D.

Ann Occup Hyg. 2005 Oct;49(7):619-28. Epub 2005 Aug 26.

PMID:
16126757
11.

Evaluation of surface contamination in a hospital hematology--oncology pharmacy.

Touzin K, Bussières JF, Langlois E, Lefebvre M.

J Oncol Pharm Pract. 2009 Mar;15(1):53-61. doi: 10.1177/1078155208096904. Epub 2008 Sep 4.

PMID:
18772214
12.

Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States.

Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA.

Am J Health Syst Pharm. 1999 Jul 15;56(14):1427-32.

PMID:
10428450
13.

Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry.

Schmaus G, Schierl R, Funck S.

Am J Health Syst Pharm. 2002 May 15;59(10):956-61. No abstract available. Erratum in: Am J Health Syst Pharm. 2002 Jul 15;59(14):1320..

PMID:
12040735
14.

Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning.

Chu WC, Hon CY, Danyluk Q, Chua PP, Astrakianakis G.

J Oncol Pharm Pract. 2012 Mar;18(1):46-51. doi: 10.1177/1078155211402106. Epub 2011 Jul 7.

PMID:
21737485
15.

The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation.

Favier B, Labrosse H, Gilles-Afchain L, Cropet C, Perol D, Chaumard N, Latour JF, Hild P.

J Oncol Pharm Pract. 2012 Mar;18(1):37-45. doi: 10.1177/1078155211401454. Epub 2011 Mar 21.

PMID:
21422148
16.

Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation.

Sessink PJ, Leclercq GM, Wouters DM, Halbardier L, Hammad C, Kassoul N.

J Oncol Pharm Pract. 2015 Apr;21(2):118-27. doi: 10.1177/1078155214522840. Epub 2014 Feb 23.

PMID:
24567041
17.

Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals.

Merger D, Tanguay C, Langlois E, Lefebvre M, Bussières JF.

Int Arch Occup Environ Health. 2014 Apr;87(3):307-13. doi: 10.1007/s00420-013-0862-0. Epub 2013 Mar 8.

PMID:
23471647
18.

Comparative parallel assessment of a transfer device in reducing 5-fluorouracil environmental contamination inside positive air pressure isolators.

Forges F, Simoens X, Chauvin F.

J Oncol Pharm Pract. 2011 Mar;17(1):61-7. doi: 10.1177/1078155210380291. Epub 2010 Aug 10.

PMID:
20699332
19.

Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study.

Berruyer M, Tanguay C, Caron NJ, Lefebvre M, Bussières JF.

J Occup Environ Hyg. 2015;12(2):87-94. doi: 10.1080/15459624.2014.949725.

PMID:
25105559
20.

Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden.

Hedmer M, Georgiadi A, Bremberg ER, Jönsson BA, Eksborg S.

Ann Occup Hyg. 2005 Oct;49(7):629-37. Epub 2005 Aug 26.

PMID:
16126760

Supplemental Content

Support Center